GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: February 16, 2005, 11:19:08 ; Search time 4 Seconds
(without alignments)
4.497 Million cell updates/sec

Title: us-10-036-342-56
Perfect score: 2242
Sequence: 1 gaatgaatacctccgaagcc.....aaaaaaaaaaaaaaaaaaaa 2242

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 3 seqs, 4012 residues

Total number of hits satisfying chosen parameters: 6

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : 56dba:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		2137.1	95.3	2152	1	AAZ65270	Human secreted pro
2	c	126.6	5.6	127	1	AAX10638	Human biallelic po
3		62.4	2.8	1733	1	AAV81394	Human tumour antig
4	c	23.8	1.1	2152	1	AAZ65270	Human secreted pro
5	c	21.4	1.0	1733	1	AAV81394	Human tumour antig
6		14.6	0.7	127	1	AAX10638	Human biallelic po

ALIGNMENTS

RESULT 1
AAZ65270
ID AAZ65270 standard; DNA; 2152 BP.
XX
AC AAZ65270;
XX
DT 23-MAR-2000 (first entry)
XX
DE Human secreted protein gene 21.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS; leukaemia;
KW therapy; chromosome 18q22-23; ds.
XX
OS Homo sapiens.
XX
PN WO9958660-A1.
XX
PD 18-NOV-1999.
XX
PF 06-MAY-1999; 99WO-US009847.
XX
PR 12-MAY-1998; 98US-0085093P.
PR 12-MAY-1998; 98US-0085094P.
PR 12-MAY-1998; 98US-0085105P.
PR 12-MAY-1998; 98US-0085180P.
PR 18-MAY-1998; 98US-0085906P.
PR 18-MAY-1998; 98US-0085920P.
PR 18-MAY-1998; 98US-0085921P.
PR 18-MAY-1998; 98US-0085922P.
PR 18-MAY-1998; 98US-0085923P.
PR 18-MAY-1998; 98US-0085924P.
PR 18-MAY-1998; 98US-0085925P.
PR 18-MAY-1998; 98US-0085927P.
PR 18-MAY-1998; 98US-0085928P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Florence K, Ni J, Rosen CA, Carter KC, Moore PA;
PI Olsen HS, Shi Y, Young PE, Wei F, Brewer LA, Soppet DR, Lafleur DW;
PI Endress GA, Ebner R;
XX
DR WPI; 2000-062296/05.
DR P-PSDB; AAY76144.
XX
PT New isolated human genes and the secreted polypeptides they encode,
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Claim 1; Page 309; 475pp; English.
XX
CC AAZ65250 to AAZ65350 represent 97 isolated human secreted protein genes.
CC This sequence was found to be present on human chromosome 18q22-23.
CC AAY76124 to AAY76223 represent the secreted proteins encoded by the 97
CC human genes. The genes and their corresponding secreted polypeptides are
CC useful for preventing, treating or ameliorating medical conditions, e.g.
CC by protein or gene therapy. Also pathological conditions can be diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new genes. Specific uses are
CC described for each of the 97 genes, based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of cancer, tumours, developmental abnormalities and foetal
CC deficiencies, blood disorders, diseases of the immune system, autoimmune
CC diseases, inflammation, allergies, Alzheimer's and cognitive disorders,
CC schizophrenia, arthritis, asthma, psoriasis, sepsis, skin disorders,
CC atherosclerosis, diabetes, cardiovascular disorders, kidney disorders,
CC digestive/endocrine disorders, infections and AIDS. The polypeptides are
CC also useful for identifying their binding partners. The sequences shown
CC in AAY76224 to AAY76424 represent fragments of the secreted proteins
XX
SQ Sequence 2152 BP; 541 A; 526 C; 531 G; 553 T; 0 U; 1 Other;

Query Match 95.3%; Score 2137.1; DB 1; Length 2152;
Best Local Similarity 99.8%; Pred. No. 4e-11;
Matches 2148; Conservative 1; Mismatches 0; Indels 3; Gaps 1;

```
Qy      19 CCGCTTTGTTCTCCAGATGTGAATAGCTCCACTATACCAGCCTCGTCTTCCTTCCGGGGG 78
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 CCGCTTTGTTCTCCAGATGTGAATAGCTCCACTATACCAGCCTCGTCTTCCTTCCGGGGG 60

Qy      79 ACAACGTGGGTCAGGGCACAGAGAGATATTTAATGTCACCCTCTTGGGGCTTTCATGGGA 138
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 ACAACGTGGGTCAGGGCACAGAGAGATATTTAATGTCACCCTCTTGGGGCTTTCATGGGA 120

Qy     139 CTCCCTCTGCCACATTTTTTGGAGGTTGGGAAAGTTGCTAGAGGCTTCAGAACTCCAGCC 198
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 CTCCCTCTGCCACATTTTTTGGAGGTTGGGAAAGTTGCTAGAGGCTTCAGAACTCCAGCC 180

Qy     199 TAATGGATCCCAAACTCGGGAGAATGGCTGCGTCCCTGCTGGCTG---TGCTGCTGCTGC 255
           ||||||||||||||||||||||||||||||||||||||||||||||   |||||||||||||
Db     181 TAATGGATCCCAAACTCGGGAGAATGGCTGCGTCCCTGCTGGCTGTGCTGCTGCTGCTGC 240
```

```
Qy      256 TGCTGGAGCGCGGCATGTTCTCCTCACCCTCCCCGCCCCCGGCGCTGTTAGAGAAAGTCT 315
Db      241 TGCTGGAGCGCGGCATGTTCTCCTCACCCTCCCCGCCCCCGGCGCTGTTAGAGAAAGTCT 300

Qy      316 TCCAGTACATTGACCTCCATCAGGATGAATTTGTGCAGACGCTGAAGGAGTGGGTGGCCA 375
Db      301 TCCAGTACATTGACCTCCATCAGGATGAATTTGTGCAGACGCTGAAGGAGTGGGTGGCCA 360

Qy      376 TCGAGAGCGACTCTGTCCAGCCTGTGCCTCGCTTCAGACAAGAGCTCTTCAGAATGATGG 435
Db      361 TCGAGAGCGACTCTGTCCAGCCTGTGCCTCGCTTCAGACAAGAGCTCTTCAGAATGATGG 420

Qy      436 CCGTGGCTGCGGACACGCTGCAGCGCCTGGGGGGCCCGTGTGGCCTCGGTGGACATGGGTC 495
Db      421 CCGTGGCTGCGGACACGCTGCAGCGCCTGGGGGGCCCGTGTGGCCTCGGTGGACATGGGTC 480

Qy      496 CTCAGCAGCTGCCCGATGGTCAGAGTCTTCCAATACCTCCCGTCATCCTGGCCGAACTGG 555
Db      481 CTCAGCAGCTGCCCGATGGTCAGAGTCTTCCAATACCTCCCGTCATCCTGGCCGAACTGG 540

Qy      556 GGAGCGATCCCACGAAAGGCACCGTGTGCTTCTACGGCCACTTGGACGTGCAGCCTGCTG 615
Db      541 GGAGCGATCCCACGAAAGGCACCGTGTGCTTCTACGGCCACTTGGACGTGCAGCCTGCTG 600

Qy      616 ACCGGGGCGATGGGTGGCTCACGGACCCCTATGTGCTGACGGAGGTAGACGGGAAACTTT 675
Db      601 ACCGGGGCGATGGGTGGCTCACGGACCCCTATGTGCTGACGGAGGTAGACGGGAAACTTT 660

Qy      676 ATGGACGAGGAGCGACCGACAACAAAGGCCCTGTCTTGGCTTGGATCAATGCTGTGAGCG 735
Db      661 ATGGACGAGGAGCGACCGACAACAAAGGCCCTGTCTTGGCTTGGATCAATGCTGTGAGCG 720

Qy      736 CCTTCAGAGCCCTGGAGCAAGATCTTCCTGTGAATATCAAATTCATCATTGAGGGGATGG 795
Db      721 CCTTCAGAGCCCTGGAGCAAGATCTTCCTGTGAATATCAAATTCATCATTGAGGGGATGG 780

Qy      796 AAGAGGCTGGCTCTGTTGCCCTGGAGGAACTTGTGGAAAAAGAAAAGGACCGATTCTTCT 855
Db      781 AAGAGGCTGGCTCTGTTGCCCTGGAGGAACTTGTGGAAAAAGAAAAGGACCGATTCTTCT 840

Qy      856 CTGGTGTGGACTACATTGTAATTTCAGATAACCTGTGGATCAGCCAAAGGAAGCCAGCAA 915
Db      841 CTGGTGTGGACTACATTGTAATTTCAGATAACCTGTGGATCAGCCAAAGGAAGCCAGCAA 900

Qy      916 TCACTTATGGAACCCGGGGGGAACAGCTACTTCATGGTGGAGGTGAAATGCAGAGACCAGG 975
Db      901 TCACTTATGGAACCCGGGGGGAACAGCTACTTCATGGTGGAGGTGAAATGCAGAGACCAGG 960

Qy      976 ATTTTCACTCAGGAACCTTTGGTGGCATCCTTCATGAACCAATGGCTGATCTGGTTGCTC 1035
Db      961 ATTTTCACTCAGGAACCTTTGGTGGCATCCTTCATGAACCAATGGCTGATCTGGTTGCTC 1020

Qy     1036 TTCTCGGTAGCCTGGTAGACTCGTCTGGTCATATCCTGGTCCCTGGAATCTATGATGAAG 1095
Db     1021 TTCTCGGTAGCCTGGTAGACTCGTCTGGTCATATCCTGGTCCCTGGAATCTATGATGAAG 1080

Qy     1096 TGGTTCCTCTTACAGAAGAGGAAATAAATACATACAAAGCCATCCATCTAGACCTAGAAG 1155
Db     1081 TGGTTCCTCTTACAGAAGAGGAAATAAATACATACAAAGCCATCCATCTAGACCTAGAAG 1140

Qy     1156 AATACCGGAATAGCAGCCGGGTTGAGAAATTTCTGTTCGATACTAAGGAGGAGATTCTAA 1215
Db     1141 AATACCGGAATAGCAGCCGGGTTGAGAAATTTCTGTTCGATACTAAGGAGGAGATTCTAA 1200

Qy     1216 TGCACCTCTGGAGGTACCCATCTCTTTCTATTCATGGGATCGAGGGCGCGTTTGATGAGC 1275
Db     1201 TGCACCTCTGGAGGTACCCATCTCTTTCTATTCATGGGATCGAGGGCGCGTTTGATGAGC 1260

Qy     1276 CTGGAACTAAAACAGTCATACCTGGCCGAGTTATAGGAAAATTTTCAATCCGTCTAGTCC 1335
Db     1261 CTGGAACTAAAACAGTCATACCTGGCCGAGTTATAGGAAAATTTTCAATCCGTCTAGTCC 1320

Qy     1336 CTCACATGAATGTGTCTGCGGTGGAAAAACAGGTGACACGACATCTTGAAGATGTGTTCT 1395
Db     1321 CTCACATGAATGTGTCTGCGGTGGAAAAACAGGTGACACGACATCTTGAAGATGTGTTCT 1380

Qy     1396 CCAAAAGAAATAGTTCCAACAAGATGGTTGTTTCCATGACTCTAGGACTACACCCGTGGA 1455
Db     1381 CCAAAAGAAATAGTTCCAACAAGATGGTTGTTTCCATGACTCTAGGACTACACCCGTGGA 1440

Qy     1456 TTGCAAATATTGATGACACCCAGTATCTCGCAGCAAAAAGAGCGATCAGAACAGTGTTTG 1515
Db     1441 TTGCAAATATTGATGACACCCAGTATCTCGCAGCAAAAAGAGCGATCAGAACAGTGTTTG 1500

Qy     1516 GAACAGAACCAGATATGATCCGGGATGGATCCACCATTCCAATTGCCAAAATGTTCCAGG 1575
Db     1501 GAACAGAACCAGATATGATCCGGGATGGATCCACCATTCCAATTGCCAAAATGTTCCAGG 1560

Qy     1576 AGATCGTCCACAAGAGCGTGGTGCTAATTCCGCTGGGAGCTGTTGATGATGGAGAACATT 1635
Db     1561 AGATCGTCCACAAGAGCGTGGTGCTAATTCCGCTGGGAGCTGTTGATGATGGAGAACATT 1620

Qy     1636 CGCAGAATGAGAAAATCAACAGGTGGAACTACATAGAGGGAACCAAATTATTTGCTGCCT 1695
Db     1621 CGCAGAATGAGAAAATCAACAGGTGGAACTACATAGAGGGAACCAAATTATTTGCTGCCT 1680

Qy     1696 TTTTCTTAGAGATGGCCCAGCTCCATTAATCACAAGAACCTTCTAGTCTGATCTGATCCA 1755
Db     1681 TTTTCTTAGAGATGGCCCAGCTCCATTAATCACAAGAACCTTCTAGTCTGATCTGATCCA 1740

Qy     1756 CTGACAGATTCACCTCCCCCACATCCCTAGACAGGGATGGAATGTAAATATCCAGAGAAT 1815
Db     1741 CTGACAGATTCACCTCCCCCACATCCCTAGACAGGGATGGAATGTAAATATCCAGAGAAT 1800

Qy     1816 TTGGGTCTAGTATAGTACATTTTCCCTTCCATTTAAAATGTCTTGGGATATCTGGATCAG 1875
Db     1801 TTGGGTCTAGTATAGTACATTTTCCCTTCCATTTAAAATGTCTTGGGATATCTGGATCAG 1860

Qy     1876 TAATAAAATATTTCAAAGGCACAGATGTTGGAAATGGTTTAAGGTCCCCCACTGCACACC 1935
Db     1861 TAATAAAATATTTCAAAGGCACAGATGTTGGAAATGGTTTAAGGTCCCCCACTGCACACC 1920

Qy     1936 TTCCTCAAGTCATAGCTGCTTGCAGCAACTTGATTTCCCCAAGTCCTGTGCAATAGCCCC 1995
Db     1921 TTCCTCAAGTCATAGCTGCTTGCAGCAACTTGATTTCCCCAAGTCCTGTGCAATAGCCCC 1980

Qy     1996 AGGATTGGATTCCTTCCAACCTTTTAGCATATCTCCAACCTTGCAATTTGATTGGCATAA 2055
Db     1981 AGGATTGGATTCCTTCCAACCTTTTAGCATATCTCCAACCTTGCAATTTGATTGGCATAA 2040

Qy     2056 TCACTCCGGTTTGCTTTCTAGGTCCTCAAGTGCTCGTGACACATAATCATTCCATCCAAT 2115
Db     2041 TCACTCCGGTTTGCTTTCTAGGTCCTCAAGTGCTCGTGACACATAATCATTCCATCCAAT 2100

Qy     2116 GATCGCCTTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAAATGTTG 2167
Db     2101 GATCGCCTTTGCTTTACCAYTCTTTCCTTTTATCTTATTAATAAAAATGTTG 2152
```

RESULT 2
AAX10638/c
ID AAX10638 standard; DNA; 127 BP.
XX
AC AAX10638;
XX
DT 30-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic DNA fragment WI-15225.
XX
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; ss.
XX
OS Homo sapiens.

XX
PN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
DR WPI; 1998-286974/25.
XX
PT New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
PS Claim 1; Page 67; 310pp; English.
XX
CC AAX10269-X12937 are human DNA fragments which contain biallelic
CC polymorphic markers which have been isolated using the primers
CC represented in AAX09121-X10268. The base occupying the polymorphic site
CC is indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
CC can be used in methods for determining polymorphic forms in an individual
CC for use in e.g. forensics, paternity testing or for phenotypic typing for
CC diseases such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan
CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
CC familial hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases
XX
SQ Sequence 127 BP; 47 A; 16 C; 36 G; 27 T; 0 U; 1 Other;

Query Match 5.6%; Score 126.6; DB 1; Length 127;
Best Local Similarity 99.2%; Pred. No. 9.2;
Matches 126; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2017 TTTTAGCATATCTCCAACCTTGCAATTTGATTGGCATAATCACTCCGGTTTGCTTTCTAG 2076
             ||||||||||||||||||||||||||||||||||||||||||||:||||||||||||||
Db        127 TTTTAGCATATCTCCAACCTTGCAATTTGATTGGCATAATCACTCCRGTTTGCTTTCTAG 68

Qy       2077 GTCCTCAAGTGCTCGTGACACATAATCATTCCATCCAATGATCGCCTTTGCTTTACCACT 2136
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         67 GTCCTCAAGTGCTCGTGACACATAATCATTCCATCCAATGATCGCCTTTGCTTTACCACT 8

Qy       2137 CTTTCCT 2143
             |||||||
Db          7 CTTTCCT 1
```

RESULT 3
AAV81394
ID AAV81394 standard; DNA; 1733 BP.
XX
AC AAV81394;
XX
DT 16-MAR-1999 (first entry)
XX
DE Human tumour antigen zsig15 coding sequence.
XX
KW Secretion; differentiation marker; tumour; epithelial cell; colon; blood;
KW breast; prostate; growth; development; antagonist; receptor; bone marrow;
KW cancer; metastasis; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 34. .1347
FT /*tag= a
FT /product= "zsig15"
XX
PN WO9850552-A1.
XX
PD 12-NOV-1998.
XX
PF 06-MAY-1998; 98WO-US009584.
XX
PR 06-MAY-1997; 97US-0045703P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Sheppard PO, Grossmann A;
XX
DR WPI; 1999-034723/03.
DR P-PSDB; AAW67722.
XX
PT New nucleic acid encoding secreted polypeptide zsig15 - used as a marker
PT for tumour cells, useful for diagnosis and treatment of cancers,
PT inflammation and hyperplasia.
XX
PS Claim 4; Page 81-84; 100pp; English.
XX
CC This sequence encodes a secreted polypeptide, designated zsig15, which is
CC a marker for differentiation in normal and tumour cells (particularly
CC epithelial cells and derived tumours of colon, breast and prostate). The
CC zsig15 protein is useful for the promotion of growth and development of
CC epithelial cells; to identify specific (ant)agonists, also where
CC conjugated to a toxin, to deliver these to cells expressing the cognate
CC receptor (e.g. to kill cells of blood, colon, breast and bone marrow
CC cancers), and to identify/isolate receptors involved in cancer
CC metastases. The sequence was isolated from a colon cancer library after
CC screening an EST (expressed sequence tag) database for sequences
CC containing putative secretion signal sequences
XX
SQ Sequence 1733 BP; 448 A; 504 C; 442 G; 339 T; 0 U; 0 Other;

Query Match 2.8%; Score 62.4; DB 1; Length 1733;
Best Local Similarity 96.9%; Pred. No. 1.3;
Matches 63; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2178 CTGNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2237
             ||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1599 CTTTCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1658

Qy       2238 AAAAA 2242
             |||||
Db       1659 AAAAA 1663
```

RESULT 4
AAZ65270/c
ID AAZ65270 standard; DNA; 2152 BP.
XX
AC AAZ65270;
XX
DT 23-MAR-2000 (first entry)
XX
DE Human secreted protein gene 21.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS; leukaemia;
KW therapy; chromosome 18q22-23; ds.